Last updated: June 2, 2026
MONOFERRIC suppliers: manufacturers, contract facilities, and supply-chain coverage for ferric derisomaltose
Executive summary: MONOFERRIC (ferric derisomaltose) supply is controlled by the product’s manufacturing and packaging network for the approved drug product and any technology transfer arrangements supporting commercial scale-up. The supplier picture depends on the labeled dosage form(s) and which U.S./EU commercial packaging configuration is being sourced. Without the drug’s specific labeled product details (strength, dosage form, and the listed manufacturer/packager for each market), a complete, accurate supplier map cannot be produced.
Who manufactures MONOFERRIC (ferric derisomaltose) for commercial supply?
Short answer: Manufacturer identification requires the drug product’s label-listed manufacturer and packager(s) for the specific market (for example, U.S. vs. EU). Those entries sit on the prescribing information and often differ by presentation and distribution segment.
What entities typically appear as MONOFERRIC manufacturers on the label?
- Drug substance supplier (iron-carbohydrate complex intermediate chain and derisomaltose conjugation)
- Drug product manufacturer (final sterile fill-finish or solution manufacture)
- Primary packaging manufacturer (vial/bottle production where applicable)
- Secondary packager and distributor (cartoning, labeling, distribution logistics)
Which companies are the contract manufacturing suppliers for MONOFERRIC vials and injection?
Short answer: Contract manufacturing organization (CMO) suppliers for sterile injectable products are identified through label “Manufactured for” and facility-name disclosures, and in some cases through FDA facility databases tied to the approved application.
What to look for in MONOFERRIC CMO disclosures
- “Manufactured by” site name and address for the injectable solution
- “Packaged by” and “Distributed by” entries
- Sterile fill-finish facility ownership vs. contracted control
What are the key drug substance and sterile fill-finish supplier steps for MONOFERRIC?
Short answer: For ferric carbohydrate injectables, the supply chain typically splits into:
- Ferric complex synthesis and derisomaltose conjugation under controlled specifications
- Solution manufacture, filtration, and sterile fill-finish
- Container closure integrity controls for vials and labeling/serialization where required
How do supplier changes show up operationally
- Site transfers appear via updated manufacturing sections in regulatory filings
- Packaging and label changes can occur even if formulation manufacturing stays at the original site
- Sterile fill-finish capacity expansions often show up as additional qualified sites
What is MONOFERRIC’s FDA/EMA manufacturing site coverage and supplier geography?
Short answer: Manufacturing site coverage is jurisdiction-specific and depends on each approved presentation’s regulatory registration. Mapping requires the label and the relevant submissions per market.
U.S. vs EU supplier coverage
- U.S.: site-level manufacturing and packaging can be mapped via FDA-registered facilities and label disclosures for the approved product
- EU: EMA product documentation links to named manufacturing and batch release sites, often different from U.S. packager names
Does MONOFERRIC have multiple suppliers or single-source risk?
Short answer: Multi-sourcing risk for injectables is assessed by whether multiple manufacturing sites are approved for the same presentation and whether the label discloses more than one manufacturing/packaging address.
Supplier risk indicators for MONOFERRIC
- Multiple label-listed sites for the same strength/form
- Availability of parallel manufacturing lanes or contract backup sites
- Evidence of recent manufacturing site additions tied to approvals or supplements
How does MONOFERRIC compare with other IV iron suppliers in their manufacturing footprints?
Short answer: Many IV iron products share similar supply-chain patterns: defined drug product sterile manufacturing sites plus contract packaging and distribution networks. The exact MONOFERRIC footprint must be confirmed from the product label and regulatory facility registration.
Comparative benchmarking criteria
- Number of approved manufacturing sites
- Existence of CMO sterilization and fill-finish operations
- Variability in presentation-specific manufacturing addresses
What supply contracts or licensing agreements affect MONOFERRIC manufacturing availability?
Short answer: Licensing and supply agreements typically affect who can manufacture under the technology and who can distribute in each geography. Supplier identity for commercial supply must be taken from label/manufacturing disclosures tied to each market authorization.
Where contract terms typically surface
- Manufacturing site additions following scale-up
- Corporate changes after transfers of manufacturing responsibility
- Market-specific distribution partnerships
Key Takeaways
- A definitive list of MONOFERRIC suppliers requires the label-identified manufacturer and packager entries for the specific approved presentation(s) and market.
- MONOFERRIC supplier coverage is usually split across drug product sterile manufacturing and packaging/distribution, with possible CMO involvement in fill-finish and secondary packaging.
- Single-source risk depends on whether multiple label-listed manufacturing/packaging sites exist for the same presentation and whether additional sites have been approved for commercial supply.
FAQs
- Which company is listed as the manufacturer of MONOFERRIC on the U.S. prescribing information?
- Are there contract manufacturing organizations (CMOs) listed for MONOFERRIC sterile fill-finish?
- Does MONOFERRIC use different manufacturing sites for different strengths or pack sizes?
- What regulatory sources list the manufacturing and packaging facilities for MONOFERRIC in the EU?
- How can purchasers verify MONOFERRIC supply chain continuity when manufacturing sites change?
References
- (No sources provided in the prompt.)
